- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor-positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 529KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 120KB)
Sacituzumab govitecan – November 2023
Sacituzumab Govitecan: Powder for injection 180 mg; Trodelvy®
Last updated
1 March 2024